NICE recommends semaglutide for obesity treatment

Updated: Feb 16

Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent. The UK regulatory body NICE has issued draft guidance recommending semaglutide (also known as Wegovy) to adults with at least one weight-related condition and a body mass index (BMI) of at least 35 kg/m2, and exceptionally, to people with a BMI of 30.0 kg/m2 to 34.9 kg/m2.

Semaglutide, developed and made by Novo Nordisk, can only be prescribed as part of a specialist weight management service with multidisciplinary input (such as a tier 3 weight management programme or tier 4 specialist obesity services including surgery service) and for a maximum of two years.


Clinical trial evidence shows that people lose more weight with semaglutide alongside supervised weight loss coaching than with the support alone. Outcomes from the STEP 1 clinical trial, a randomised double-blind trial, showed that participants taking semaglutide lost on average 12% more of their body weight compared with placebo.


Patients inject themselves once a week with pens pre-filled with semaglutide. The drug suppresses appetite by mimicking the hormone glucagon-like peptide-1 (GLP-1), which is released after eating. It makes people using it feel full, thereby resulting in people eating less and reducing their overall calorie intake.


The 2019 Health Survey for England estimated 28% of adults in England had obesity and a further 36% were overweight. Government estimates indicate that the current costs of obesity in the UK are £6.1 billion to the NHS and £27 billion to wider society.

Helen Knight, programme director in the centre for health technology evaluation at NICE, said: “We know that management of overweight and obesity is one of the biggest challenges our health service is facing with nearly two thirds of adults either overweight or obese. It is a lifelong condition that needs medical intervention, has psychological and physical effects, and can affect quality of life. But in recent years NICE has been able to recommend a new line of pharmaceutical treatments which have shown that those people using them, alongside changes to their diet and exercise, have been able to reduce their weight.”

The list price of semaglutide 2.4 mg and 1.7 mg is commercial in confidence and cannot be reported here. The list price of semaglutide 0.25 mg, 0.5 mg and 1.0 mg is £73.25 per pack (4 pre-filled pens; excluding VAT).


NICE’s independent appraisal committee has recommended that semaglutide can be offered as an option for weight management, alongside a reduced-calorie diet and increased physical activity in adults, only if:

  • they have at least one weight-related comorbidity and:

  • a BMI at least 35.0 kg/m2, or

  • exceptionally, a BMI of 30.0 kg/m2 to 34.9 kg/m2 if they are referred to tier 3 services based on the criteria in NICE’s clinical guideline on obesity: identification, assessment and management.

  • A lower BMI threshold (usually reduced by 2.5 kg/m2) has been recommended for people from south Asian, Chinese, and Black African or Caribbean family backgrounds, following recommendations in NICE’s guideline on preventing ill health and premature death in black, Asian and other minority ethnic groups.